Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2008

PDL to Pay Shareholders $500M to Spin Out Biotech Business

  • PDL BioPharma is spinning off its biotechnology R&D operations to concentrate on its antibody licensing franchise and will pay shareholders a $500 million dividend. In October the company began looking for a buyer but has since only managed to sell a part of its business, its cardiovascular segment, to EKR Therapeutics.

    Shareholders will receive a cash dividend of $4.25 per share of common stock, financed by the EKR deal and the sale of PDL’s biologic manufacturing facility to Genmab. The EKR transaction is valued at $170 million, while PDL received $240 million from Genmab.

    PDL plans to capitalize the new company with approximately $375 million in cash at the completion of the transaction, expected by the end of this year. This seed money along with other fees will fund the spin-off for approximately three years, according to PDL. Anticipated future payments include potential milestone fees and certain royalties.

    The original PDL will focus on its antibody humanization royalty assets. The company plans to distribute future related revenues, net of any operating expenses, debt service, and income taxes, to its stockholders and does not intend to make any acquisitions or engage in any material capital expenditures. The firm says that it will require a nominal number of employees to continue this business.

    PDL anticipates 2008 royalty revenues to be $240 million to $260 million, up from $221.1 million in 2007. Earnings are related to antibody products including Avastin, Herceptin, Xolair, Raptiva, Lucentis, Synagis, Tysabri, and Mylotarg.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »